Expert: Dual-mechanism antiepileptic that binds SV2A (similar to levetiracetam/brivaracetam) and positively modulates GABAA receptors, providing synergistic anticonvulsant activity.

Everyday: Works on two brain targets to reduce seizures - one that controls brain chemical release and one that calms nerve activity.

Targets: ["SV2A","GABA-A"]

Padsevonil - Drug-Resistant Epilepsy - Ph3 - Updates 2026

Dual-mechanism anticonvulsant combining SV2A modulation with GABA-A receptor positive allosteric modulation for drug-resistant epilepsy. Novel approach targeting two synergistic pathways for treatment-refractory seizures.